NasdaqGS:INSMBiotechs
Should TPIP’s New Clinical Data and Analyst Coverage Require Action From Insmed (INSM) Investors?
Insmed recently announced that it will present four abstracts on its treprostinil palmitil inhalation powder (TPIP) program for pulmonary arterial hypertension at the Pulmonary Vascular Research Institute 2026 congress, including Phase 2b topline results and Phase 3 trial design, and it also received new analyst coverage from Barclays.
This combination of fresh clinical insight into TPIP and expanded analyst attention highlights how Insmed’s pulmonary pipeline is gaining increased medical...